GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Spectral AI Inc (NAS:MDAI) » Definitions » Debt-to-EBITDA

MDAI (Spectral AI) Debt-to-EBITDA : -2.66 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Spectral AI Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Spectral AI's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $5.19 Mil. Spectral AI's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.87 Mil. Spectral AI's annualized EBITDA for the quarter that ended in Sep. 2024 was $-3.02 Mil. Spectral AI's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -2.66.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Spectral AI's Debt-to-EBITDA or its related term are showing as below:

MDAI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.04   Med: -0.14   Max: -0.11
Current: -1.04

During the past 3 years, the highest Debt-to-EBITDA Ratio of Spectral AI was -0.11. The lowest was -1.04. And the median was -0.14.

MDAI's Debt-to-EBITDA is ranked worse than
100% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.54 vs MDAI: -1.04

Spectral AI Debt-to-EBITDA Historical Data

The historical data trend for Spectral AI's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectral AI Debt-to-EBITDA Chart

Spectral AI Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.14 -0.58 -0.11

Spectral AI Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.11 -0.12 -0.82 -1.11 -2.66

Competitive Comparison of Spectral AI's Debt-to-EBITDA

For the Medical Devices subindustry, Spectral AI's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectral AI's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Spectral AI's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Spectral AI's Debt-to-EBITDA falls into.



Spectral AI Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Spectral AI's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.289 + 0) / -12.262
=-0.11

Spectral AI's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.186 + 2.87) / -3.024
=-2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Spectral AI  (NAS:MDAI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Spectral AI Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Spectral AI's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectral AI Business Description

Traded in Other Exchanges
N/A
Address
2515 McKinney Avenue, Suite 1000, Dallas, TX, USA, 75201
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
Executives
John Michael Dimaio 10 percent owner 6125 LUTHER LANE, DALLAS TX 75225
Michael Patrick Murphy director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Els 1960 Family, L.p. 10 percent owner 2323 VICTORY AVE., SUITE. 700, DALLAS TX 75219
Richard John Cotton director RUE DU VILLAGE 4, CHAMPERY V8 1874
Mellish Martin C.b. director 13 BERRILL FARMS LN, HANOVER NH 03755
Jeffrey Edward Thatcher officer: Chief Scientist 6659 ESCONDIDO ST, IRVING TX 75039
Nils Windler officer: Chief Financial Officer 8602 NAPA LANDING, SAN ANTONIO TX 78015
Wensheng Fan director, officer: CHIEF EXECUTIVE OFFICER 3320 SPRING MOUNTAIN DRIVE, PLANO TX 75025
Vincent S. Capone officer: GENERAL COUNSEL 1620 GRASSHOPPER LANE, LOWER GWYNEDD PA 19002
Nikolaos Pagoulatos officer: CHIEF OPERATING OFFICER 5122 IROQUOIS DR, FRISCO TX 75034
Xiaojia Cynthia Cai director 10 CELESTIAL WAY, NEWARK DE 19711
Heather Bellini director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Edmonds Franklin S. Jr. director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Rosecliff Acquisition Sponsor I Llc director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Erich Spangenberg 10 percent owner 73 595 EL PASEO, SUITE 2204, PALM DESERT CA 92260